JP2023553701A5 - - Google Patents
Info
- Publication number
- JP2023553701A5 JP2023553701A5 JP2023536885A JP2023536885A JP2023553701A5 JP 2023553701 A5 JP2023553701 A5 JP 2023553701A5 JP 2023536885 A JP2023536885 A JP 2023536885A JP 2023536885 A JP2023536885 A JP 2023536885A JP 2023553701 A5 JP2023553701 A5 JP 2023553701A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- protein
- sequence
- nucleic acid
- transposase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20214691 | 2020-12-16 | ||
| EP20214691.6 | 2020-12-16 | ||
| EP21209721 | 2021-11-22 | ||
| EP21209721.6 | 2021-11-22 | ||
| PCT/EP2021/086333 WO2022129430A1 (en) | 2020-12-16 | 2021-12-16 | Therapeutic lama2 payload for treatment of congenital muscular dystrophy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023553701A JP2023553701A (ja) | 2023-12-25 |
| JP2023553701A5 true JP2023553701A5 (https=) | 2024-12-23 |
Family
ID=79269765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023536885A Pending JP2023553701A (ja) | 2020-12-16 | 2021-12-16 | 先天性筋ジストロフィーの処置のための治療用ｌａｍａ２ペイロード |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250269057A1 (https=) |
| EP (1) | EP4263818A1 (https=) |
| JP (1) | JP2023553701A (https=) |
| KR (1) | KR20230125806A (https=) |
| AU (1) | AU2021399929A1 (https=) |
| CA (1) | CA3202411A1 (https=) |
| WO (1) | WO2022129430A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118185901B (zh) * | 2022-12-12 | 2025-03-21 | 北京精缮生物科技有限责任公司 | 一种PBase蛋白、融合蛋白、核酸和基因整合系统及应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8048999B2 (en) | 2005-12-13 | 2011-11-01 | Kyoto University | Nuclear reprogramming factor |
| JP5813321B2 (ja) | 2007-03-23 | 2015-11-17 | ウィスコンシン アラムニ リサーチ ファンデーション | 体細胞の再プログラム化 |
| JP2018513681A (ja) * | 2015-03-31 | 2018-05-31 | エクセリゲン サイエンティフィック, インコーポレイテッドExeligen Scientific, Inc. | 細胞または生物のゲノムへのＤＮＡ配列の標的化組み込みのためのＣａｓ９レトロウイルスインテグラーゼおよびＣａｓ９レコンビナーゼ系 |
| US20200095579A1 (en) * | 2017-02-22 | 2020-03-26 | Crispr Therapeutics Ag | Materials and methods for treatment of merosin-deficient cogenital muscular dystrophy (mdcmd) and other laminin, alpha 2 (lama2) gene related conditions or disorders |
| WO2018175872A1 (en) * | 2017-03-24 | 2018-09-27 | President And Fellows Of Harvard College | Methods of genome engineering by nuclease-transposase fusion proteins |
| US20220235379A1 (en) * | 2019-06-11 | 2022-07-28 | Universitat Pompeu Fabra | Targeted gene editing constructs and methods of using the same |
-
2021
- 2021-12-16 JP JP2023536885A patent/JP2023553701A/ja active Pending
- 2021-12-16 CA CA3202411A patent/CA3202411A1/en active Pending
- 2021-12-16 EP EP21839193.6A patent/EP4263818A1/en active Pending
- 2021-12-16 US US18/258,028 patent/US20250269057A1/en active Pending
- 2021-12-16 WO PCT/EP2021/086333 patent/WO2022129430A1/en not_active Ceased
- 2021-12-16 KR KR1020237023945A patent/KR20230125806A/ko active Pending
- 2021-12-16 AU AU2021399929A patent/AU2021399929A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12486521B2 (en) | Platform for expressing protein of interest in liver | |
| ES2780904T3 (es) | Edición genómica usando nickasas Cas9 | |
| US20250367322A1 (en) | Nucleobase editing system and method of using same for modifying nucleic acid sequences | |
| CN116419975A (zh) | 使用以位点特异性靶向元件实现的可编程添加（paste）来进行位点特异性遗传改造的系统、方法和组合物 | |
| AU2019365100B2 (en) | Genome editing by directed non-homologous DNA insertion using a retroviral integrase-Cas9 fusion protein | |
| TW202421205A (zh) | 基因編輯組分、系統及使用方法 | |
| EP4452335A1 (en) | Co-delivery of a gene editor construct and a donor template | |
| US20250290100A1 (en) | SINGLE pegRNA-MEDIATED LARGE INSERTIONS | |
| US20250340901A1 (en) | Gene editing components, systems, and methods of use | |
| WO2025049959A9 (en) | Gene editing systems, compositions, and methods for treatment of vexas syndrome | |
| JP2023553701A5 (https=) | ||
| WO2024238321A1 (en) | Compositions and methods for targeted epigenetic modification | |
| Meir et al. | Transposon-based vector systems for gene therapy clinical trials: challenges and considerations | |
| US20250179454A1 (en) | Fusion proteins and uses thereof for precision editing | |
| US20220154221A1 (en) | Site specific recombinase integrase variants and uses thereof in gene editing in eukaryotic cells | |
| TW202546224A (zh) | 新穎的ｒｎａ引導之核酸酶及用於聚合酶編輯之蛋白質 | |
| Preuss et al. | Comparison between the interactions of adenovirus-derived peptides with plasmid DNA and their role in gene delivery mediated by liposome–peptide–DNA virus-like nanoparticles | |
| JP2024515715A (ja) | レトロウイルスインテグラーゼ－Ｃａｓ融合タンパク質を使用した指向性非相同ＤＮＡ挿入によるゲノム編集及び治療の方法 | |
| CN117561331A (zh) | 用于产生经基因修饰的原代细胞的方法和组合物 | |
| US20240084274A1 (en) | Gene editing components, systems, and methods of use | |
| Recchia et al. | Site-specific integration into the human genome: ready for clinical application? | |
| WO2025224107A1 (en) | Method and compositions for detecting off-target editing | |
| WO2025187834A1 (en) | Method for treating muscular dystrophy by targeting lama1 gene | |
| JP2025516484A5 (https=) | ||
| Bertolotti | Gene therapy: transient or long-term minigene expression and gene repair/inactivation |